Aliform develops the Celluleaf medical device for performing blunt dissection in skin surgery, specifically targeting conditions like cellulite, scars, and skin grafting. This device enhances the safety and efficacy of minimally invasive procedures by minimizing tissue damage during surgery.
Funding
$1.7M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Minimally invasive skin surgeries, such as those targeting cellulite or scars, require precise blunt dissection to minimize tissue damage and improve patient outcomes. Traditional surgical methods may lack the necessary precision, potentially leading to complications and suboptimal aesthetic results.
Solution
Aliform's Celluleaf is a medical device designed to enhance the safety and efficacy of blunt dissection in skin surgery. Developed in collaboration with clinicians, Celluleaf enables minimally invasive procedures for treating conditions like cellulite, scars, and facilitating skin grafting. The device aims to provide surgeons with a more controlled and precise tool, reducing the risk of tissue trauma and improving the overall quality of surgical outcomes. By focusing on low-risk technologies and preclinical evidence, Aliform seeks to address challenges faced by plastic surgeons and dermatologists in practice.
Target Audience
The primary target audience includes plastic surgeons and dermatologists performing minimally invasive skin surgeries, particularly those focused on cellulite treatment, scar revision, and skin grafting procedures.
Features
- Specialized design for performing blunt dissection in minimally invasive procedures.
- Optimized for use in cellulite treatment, scar revision, and skin grafting.
- Developed in collaboration with clinicians to meet the specific needs of skin surgery.
- Focus on minimizing tissue damage during surgical procedures.